How Pfizer makes money
Fiscal 2025, year ended Dec 31, 2025 · 10-K filed with the SEC
Pfizer brought in $62.6B of revenue in fiscal 2025 (−1.6% on the year before). It kept 74.3% after the cost of what it sold. Net income was $7.77B.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Fiscal 2025, year ended Dec 31, 2025 · 10-K filed with the SEC
Pfizer brought in $62.6B of revenue in fiscal 2025 (−1.6% on the year before). It kept 74.3% after the cost of what it sold. Net income was $7.77B.
By region, United States accounted for 59% and Developed Markets for 26% of revenue.
Fiscal 2025, year ended Dec 31, 2025, from the revenue Pfizer broke down in its 10-K filed Feb 26, 2026. The split is the company’s own; regions are usually where customers are billed, not where products end up.
| Line | Fiscal 2024 | Fiscal 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $63.6B | $62.6B | −$1.05B | −1.6% |
| Pre-tax profit | $8.02B | $7.52B | −$503M | −6.3% |
| Expenses and provisions | $55.6B | $55.1B | −$545M | −1.0% |
| Tax benefit | $28M | $266M | +$238M | +850.0% |
| Net income | $8.03B | $7.77B | −$260M | −3.2% |
| Interest and other | $20M | $15M | −$5M | −25.0% |
| In US dollars | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.8B | $52.5B | $40.8B | $40.9B | $41.7B | $81.3B | $101B | $59.6B | $63.6B | $62.6B |
| Growth | +2.4% | −0.5% | −22.3% | +0.2% | +1.8% | +95.2% | +24.5% | −41.1% | +6.8% | −1.6% |
| Cost of revenue | $12.3B | $11.2B | $8.99B | $8.05B | $8.48B | $30.8B | $34.3B | $25B | $17.9B | $16.1B |
| Gross profit | $40.5B | $41.3B | $31.8B | $32.9B | $33.2B | $50.5B | $66.8B | $34.6B | $45.8B | $46.5B |
| Gross margin | 76.7% | 78.6% | 78.0% | 80.3% | 79.6% | 62.1% | 66.1% | 58.1% | 71.9% | 74.3% |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Sales, general and admin | — | — | — | — | — | — | — | — | — | — |
| Other operating costs | — | — | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — |
| Interest expense | $1.19B | $1.27B | $1.32B | $1.57B | $1.45B | $1.29B | $1.24B | $2.21B | $3.09B | $2.67B |
| Pre-tax income | $8.35B | $12.3B | $3.59B | $11.3B | $7.04B | $24.3B | $34.7B | $1.06B | $8.02B | $7.52B |
| Income tax | $1.12B | −$9.05B | −$266M | $583M | $370M | $1.85B | $3.33B | −$1.11B | −$28M | −$266M |
| Effective tax rate | 13.4% | — | — | 5.1% | 5.3% | 7.6% | 9.6% | — | — | — |
| Net income | $7.21B | $21.3B | $11.2B | $16B | $9.16B | $22B | $31.4B | $2.12B | $8.03B | $7.77B |
| Net margin | 13.7% | 40.6% | 27.3% | 39.2% | 22.0% | 27.0% | 31.0% | 3.6% | 12.6% | 12.4% |
“—” means the company did not tag that line that year in the standard US taxonomy, not zero. Banks and insurers report no gross or operating profit. “Sales, general and admin” adds sales and marketing to general and administrative when the company reports them apart. Other operating costs are what is left between gross and operating profit after the lines the company tagged.
Twenty years of cash flow, buybacks and debt: Pfizer financial history. Margins and valuation next to its industry: Pfizer vs its peers. The latest quarter, insider trades and fund moves: Pfizer (PFE) on OQRO.
By region, United States accounted for 59% and Developed Markets for 26% of revenue.
Pfizer: Biopharmaceutical medicines and vaccines. It is listed in the Pharmaceuticals industry, Health Care sector.
Pfizer splits its revenue into 3 regions: United States $37.1B (59%), Developed Markets $16.2B (26%) and Emerging Markets $9.31B (15%). Figures for fiscal 2025, from its 10-K.
$62.6B, in the fiscal year that ended Dec 31, 2025, as reported in its 10-K. That is −1.6% on fiscal 2024 ($63.6B).
74.3% in fiscal 2025: revenue of $62.6B minus a cost of revenue of $16.1B left a gross profit of $46.5B.
Net income of $7.77B and income tax of −$266M.
The SEC’s companyfacts data: the full-year figures Pfizer tagged in XBRL in its annual reports (10-K, 20-F or 40-F). When a later report restates a year, the later figure is used. Revenue, cost of revenue, gross profit, research and development, selling, general and administrative costs, operating income, pre-tax income, income tax and net income are the company’s own lines.
Lines marked * are differences: other operating costs are gross profit minus operating profit minus the cost lines the company tagged; “interest and other” is operating profit minus tax minus net income, so it holds interest, investment gains and losses, minority stakes and discontinued operations together. When the tagged cost of revenue and gross profit disagree, the company’s gross profit is kept. The segment, product and region splits come from the dimensioned revenue facts of the latest annual report’s XBRL instance: a split is shown only when its parts add up to the company’s total revenue within 1%, and labels are the company’s own. This page describes the past and is not investment advice. No language model wrote it.